BURNABY, British Columbia – January 14, 2014 - LED Medical Diagnostics has signed an agreement with the BC Cancer Agency to form a collaborative relationship with Genome British Columbia (Genome BC) to create and commercialize a progression-risk assessment test for oral cancer, according to Dentaltown. The test, the first of its kind for oral cancer, is based on a quantifiable genetic phenomenon known as “Loss of Heterozygosity,” or “LOH.”

To read the full article, click here.